Methods of treating patients at risk for renal injury and renal failure
The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
1. A method of treating a patient at risk for having suffered kidney injury or kidney disease progression comprising:
(a) performing an assay to determine the level of cyclin-dependent kinase inhibitor p21 in the patient; and
(b) if the patient exhibits an elevated level of the cyclin-dependent kinase inhibitor p21, treating the patient to reduce the risk of further kidney injury, wherein the treatment comprises one or more of administration of one or more steroids, ACE inhibitors, nuclear factor erythroid 2-related factor 2 (NRF2) activators, Angiotensin II receptor blockers, antioxidants, aldosterone antagonists, anti-inflammatory, anti-fibrotic, vasopressin antagonists, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, immunosuppressive agents, organ protection with a combination of iron or iron sucrose and a heme protein degradation inhibitor, or acute kidney injury treatments, or the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration, wherein the cyclin-dependent kinase inhibitor p21 is of SEQ ID NO. 1, wherein (a) performing an assay to determine the level of p21 in the patient, also comprises performing an assay to determine the level of microalbumin, ferritin, hemopexin, and haptoglobin in the patient.
2. A method of treating a patient determined to be at risk for future kidney injury comprising:
(a) performing an assay to determine the level of the cyclin-dependent kinase inhibitor p21 in the patient;
(b) performing an assay to determine the level of urinary albumin in the patient; and
(c) if the patient exhibits elevated levels of the cyclin-dependent kinase inhibitor p21 and albumin, treating the patient to reduce the risk of further kidney injury, wherein the treatment comprises one or more of administration of one or more steroids, ACE inhibitors, NRF2 activators, antioxidants, aldosterone antagonists, anti-inflammatory, anti-fibrotic, vasopressin antagonists, SGLT-2 inhibitors, immunosuppressive agents, organ protection with a combination of iron or iron sucrose and a heme protein degradation inhibitor, or acute kidney injury treatments, or the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration, wherein the cyclin-dependent kinase inhibitor p21 is of SEQ ID NO. 1, wherein (a) performing an assay to determine the level of p21 in the patient, also comprises performing an assay to determine the level of microalbumin, ferritin, hemopexin, and haptoglobin in the patient.
3. A method of treating a patient at risk for having suffered kidney injury or kidney disease progression comprising:
(a) performing an assay to determine the level of cyclin-dependent kinase inhibitor p21 in the patient; and
(b) if the patient exhibits an elevated level of the cyclin-dependent kinase inhibitor p21, treating the patient to reduce the risk of further kidney injury, wherein the treatment comprises one or more of administration of one or more steroids, ACE inhibitors, nuclear factor erythroid 2-related factor 2 (NRF2) activators, Angiotensin II receptor blockers, antioxidants, aldosterone antagonists, anti-inflammatory, anti-fibrotic, vasopressin antagonists, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, immunosuppressive agents, organ protection with a combination of iron or iron sucrose and a heme protein degradation inhibitor, or acute kidney injury treatments, or the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration, wherein the cyclin-dependent kinase inhibitor p21 is of SEQ ID NO. 1, wherein the patient has undergone a kidney transplant.
4. A method of treating a patient determined to be at risk for future kidney injury comprising:
(a) performing an assay to determine the level of the cyclin-dependent kinase inhibitor p21 in the patient;
(b) performing an assay to determine the level of urinary albumin in the patient; and
(c) if the patient exhibits elevated levels of the cyclin-dependent kinase inhibitor p21 and albumin, treating the patient to reduce the risk of further kidney injury, wherein the treatment comprises one or more of administration of one or more steroids, ACE inhibitors, NRF2 activators, antioxidants, aldosterone antagonists, anti-inflammatory, anti-fibrotic, vasopressin antagonists, SGLT-2 inhibitors, immunosuppressive agents, organ protection with a combination of iron or iron sucrose and a heme protein degradation inhibitor, or acute kidney injury treatments, or the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration, wherein the cyclin-dependent kinase inhibitor p21 is of SEQ ID NO. 1, wherein the patient has undergone a kidney transplant.